Retatrutide, by Soma Corp., is attracting significant attention as a novel treatment for metabolic management . This unique drug merges the activity of a GLP-1 receptor agonist and a GIP receptor stimulant, intended to effectively promote weight loss but also improve related metabolic conditions . Preliminary clinical studies have indicated promisi